Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $48.4 million.

  • Janux Therapeutics' Cash & Equivalents rose 8086.64% to $48.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.4 million, marking a year-over-year increase of 8086.64%. This contributed to the annual value of $430.6 million for FY2024, which is 214215.05% up from last year.
  • As of Q3 2025, Janux Therapeutics' Cash & Equivalents stood at $48.4 million, which was up 8086.64% from $52.4 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Cash & Equivalents ranged from a high of $430.6 million in Q4 2024 and a low of $14.7 million during Q2 2024
  • In the last 5 years, Janux Therapeutics' Cash & Equivalents had a median value of $51.9 million in 2022 and averaged $101.4 million.
  • As far as peak fluctuations go, Janux Therapeutics' Cash & Equivalents plummeted by 8139.94% in 2022, and later skyrocketed by 214215.05% in 2024.
  • Janux Therapeutics' Cash & Equivalents (Quarter) stood at $35.6 million in 2021, then soared by 44.53% to $51.4 million in 2022, then plummeted by 62.66% to $19.2 million in 2023, then skyrocketed by 2142.15% to $430.6 million in 2024, then plummeted by 88.76% to $48.4 million in 2025.
  • Its Cash & Equivalents was $48.4 million in Q3 2025, compared to $52.4 million in Q2 2025 and $73.7 million in Q1 2025.